Natixis Advisors, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 10,453 shares of ALNY stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,453
Previous 10,002
4.51%
Holding current value
$2.68 Million
Previous $2.75 Million
10.58%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ALNY
# of Institutions
673Shares Held
112MCall Options Held
943KPut Options Held
922K-
Capital World Investors Los Angeles, CA16.6MShares$4.26 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.27 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.45 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.79 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.12 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $31.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...